• FOLD

Earnings call: Amicus Therapeutics reports robust Q3 growth, raises guidance

Amicus Therapeutics reported a 37% revenue growth in Q3 2024, driven by Galafold sales, raising guidance for the year while addressing challenges in patient additions and legal issues.